权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional consequences of FHC mutations in cardiac MyBPC

心脏 MyBPC 中 FHC 突变的功能后果

基本信息

批准号：
9206516
负责人：
Julian Stelzer
金额：
$ 39.63万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-02-01 至 2019-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9206516
关键词：
ATP phosphohydrolase Acceleration Accounting Actins Actomyosin Acute Address Adolescent and Young Adult Adult Affect Agonist Alleles Animals Behavior Cardiac Cardiac Muscle Contraction Cardiac Myosins Cardiomyopathies Catheterization Child Complementary DNA Congenital cardiomyopathy Contractile Proteins Data Defect Dependency Development Dilated Cardiomyopathy Disease Dose Familial Hypertrophic Cardiomyopathy Family suidae Fiber Foundations Functional disorder Gene Transfer Generations Goals Heart Heart Arrest Heart Diseases Heart failure Human Hypertrophic Cardiomyopathy Impairment Infusion procedures Inherited Kinetics Label Laboratories Link Magnetic Resonance Imaging Measures Mechanics Mediating Microfilaments Missense Mutation Molecular Morphology Mus Muscle function Mutation Myocardial dysfunction Myocardium Myopathy Myosin ATPase Organ Population Proteins Recombinants Regulation Relaxation Resolution Role Sarcomeres Severity of illness Skin Stress Structure Subfamily lentivirinae Sudden Death Techniques Testing Thick Filament Thin Filament Ventricular Workload design disease-causing mutation effective therapy electric impedance experimental study hemodynamics improved in vivo insight mutant myosin-binding protein C novel novel therapeutics pressure protein protein interaction protein reconstitution public health relevance reconstitution treatment strategy young adult

项目摘要

DESCRIPTION (provided by applicant): The long-range goal of this proposal is to define the mechanisms by which mutations in cardiac myosin binding protein C (MyBPC) cause hypertrophic (HCM) and dilated cardiomyopathy (DCM), a disease that affects 0.2% of the population worldwide, and is the leading cause of sudden death in young adults. Mutations in MyBPC are among the most common causes of inherited cardiomyopathy accounting for more than 40% of all known cases, and are associated with heart failure and sudden cardiac arrest. Because MyBPC is a critical modulator of actomyosin interactions, the initial functional deficit caused by mutations in MyBPC is expected to manifest as a defect in the regulation of cardiac muscle contraction at the myofilament level. However, the precise molecular mechanisms by which mutations in MyBPC alter contractile function and cause disease are not understood, and it has yet to be established if MyBPC expressing mutations can incorporate into the sarcomere to directly alter contractile function. A lack of fundamental insights into how MyBPC mutations cause HCM and DCM severely limits our ability to devise effective therapies to overcome the disease and its functional consequences. The proposed experiments will elucidate the functional effects of mutations in MyBPC known to cause a range of disease severity in children and adults, and will test the hypothesis that missense mutations in MyBPC incorporate into the sarcomere to directly alter contractile function in three principal aims designed to: 1) Establish the functional effects of MyBPC mutations on the Ca2+-dependencies of steady-state force and dynamic cross-bridge function in cardiac fibers reconstituted with MyBPC expressing HCM and DCM causing mutations, 2) Define the effects of MyBPC mutations on ATPase activity, thin filament regulation of force generation, and cross-bridge kinetics, using steady-state and transient kinetic analysis of fluorescently labeled proteins, and 3) Determine the in vivo functional consequences of missense mutations in MyBPC by assessing ventricular structure and function using pressure-volume catheterization and high resolution cardiac magnetic resonance imaging in animals subjected to acute gene transfer of mutant MyBPC. It is expected that results from these integrative studies will provide novel insights of the underlying mechanisms by which mutations in MyBPC cause cardiac dysfunction and will aid in the development of novel therapeutic strategies for treatment MyBPC related HCM and DCM.

描述(申请人提供)：这项建议的长期目标是确定心肌肌球蛋白结合蛋白C(MyBPC)突变导致肥厚性(HCM)和扩张型心肌病(DCM)的机制，这是一种影响全球0.2%人口的疾病，是导致年轻人猝死的主要原因。MyBPC基因突变是遗传性心肌病最常见的原因之一，占所有已知病例的40%以上，并与心力衰竭和心脏骤停有关。由于MyBPC是肌动蛋白相互作用的关键调节器，MyBPC突变导致的最初功能缺陷可能表现为肌丝水平上的心肌收缩调节缺陷。然而，MyBPC基因突变改变收缩功能和导致疾病的确切分子机制尚不清楚，并且MyBPC表达的突变是否能结合到肌节中直接改变收缩功能还有待确定。缺乏对MyBPC突变如何导致HCM和DCM的基本见解，严重限制了我们设计有效治疗方法来克服疾病及其功能后果的能力。拟议的实验将阐明已知的MyBPC突变对儿童和成人一系列疾病严重程度的功能影响，并将检验MyBPC错义突变并入肌节以直接改变收缩功能的假设，其主要目的是：1)建立MyBPC突变对由表达HCM和DCM的MyBPC重组的心肌纤维中的稳态力和动态交叉桥功能的钙依赖性的功能影响，2)使用荧光标记蛋白的稳态和瞬时动力学分析，确定MyBPC突变对ATPase活性、力产生的细丝调节和交叉桥动力学的影响，3)通过压力-容量导管法和高分辨率心脏磁共振成像对急性转移突变的MyBPC的心脏结构和功能进行评估，以确定MyBPC错义突变的体内功能后果。预计这些综合研究的结果将为MyBPC突变导致心功能障碍的潜在机制提供新的见解，并将有助于开发治疗MyBPC相关的HCM和DCM的新治疗策略。